JP2005517647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517647A5 JP2005517647A5 JP2003550773A JP2003550773A JP2005517647A5 JP 2005517647 A5 JP2005517647 A5 JP 2005517647A5 JP 2003550773 A JP2003550773 A JP 2003550773A JP 2003550773 A JP2003550773 A JP 2003550773A JP 2005517647 A5 JP2005517647 A5 JP 2005517647A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- schizophrenia
- norepinephrine reuptake
- selective norepinephrine
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 7
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical group O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 5
- 229960002430 atomoxetine Drugs 0.000 claims 5
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010305 Confusional state Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001495 Disorganized Schizophrenia Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- 0 *c(cccc1)c1OC(CCN*)c1ccccc1 Chemical compound *c(cccc1)c1OC(CCN*)c1ccccc1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33917401P | 2001-12-11 | 2001-12-11 | |
| PCT/US2002/036132 WO2003049724A1 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517647A JP2005517647A (ja) | 2005-06-16 |
| JP2005517647A5 true JP2005517647A5 (cg-RX-API-DMAC10.html) | 2006-01-26 |
Family
ID=23327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550773A Pending JP2005517647A (ja) | 2001-12-11 | 2002-11-27 | ノルエピネフリン再取り込み阻害物質の認知不全処置への使用 |
Country Status (26)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001705A (es) * | 2002-08-14 | 2005-04-19 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para el tratamiento de sofocos. |
| WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
| US20070105960A1 (en) * | 2003-08-27 | 2007-05-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20100317730A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Treatment for menopausal and perimenopausal vasomotor symptons |
| TW201107485A (en) * | 2009-07-31 | 2011-03-01 | Univ Nat Taiwan | Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1) |
| US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2962687B1 (en) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| ATE305788T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| SK4732002A3 (en) * | 1999-10-13 | 2002-12-03 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
-
2002
- 2002-11-27 JP JP2003550773A patent/JP2005517647A/ja active Pending
- 2002-11-27 US US10/496,765 patent/US20050009925A1/en not_active Abandoned
- 2002-11-27 KR KR10-2004-7009039A patent/KR20040066895A/ko not_active Withdrawn
- 2002-11-27 EP EP02789574A patent/EP1458368B1/en not_active Expired - Lifetime
- 2002-11-27 BR BR0213581-7A patent/BR0213581A/pt not_active IP Right Cessation
- 2002-11-27 HR HR20040528A patent/HRPK20040528B3/xx not_active IP Right Cessation
- 2002-11-27 AU AU2002352625A patent/AU2002352625A1/en not_active Abandoned
- 2002-11-27 DE DE60223718T patent/DE60223718T2/de not_active Expired - Fee Related
- 2002-11-27 ES ES02789574T patent/ES2295435T3/es not_active Expired - Lifetime
- 2002-11-27 CA CA002467802A patent/CA2467802A1/en not_active Abandoned
- 2002-11-27 SK SK244-2004A patent/SK2442004A3/sk not_active Application Discontinuation
- 2002-11-27 MX MXPA04005716A patent/MXPA04005716A/es not_active Application Discontinuation
- 2002-11-27 NZ NZ532065A patent/NZ532065A/en unknown
- 2002-11-27 HU HU0402619A patent/HUP0402619A3/hu unknown
- 2002-11-27 PL PL02369311A patent/PL369311A1/xx unknown
- 2002-11-27 WO PCT/US2002/036132 patent/WO2003049724A1/en not_active Ceased
- 2002-11-27 CZ CZ2004709A patent/CZ2004709A3/cs unknown
- 2002-11-27 IL IL16198902A patent/IL161989A0/xx unknown
- 2002-11-27 EA EA200400793A patent/EA200400793A1/ru unknown
- 2002-11-27 CN CNA028247264A patent/CN1713900A/zh active Pending
- 2002-12-05 MY MYPI20024591A patent/MY136367A/en unknown
- 2002-12-05 TW TW091135296A patent/TW200300672A/zh unknown
-
2004
- 2004-05-31 ZA ZA200404274A patent/ZA200404274B/en unknown
- 2004-06-09 EC EC2004005145A patent/ECSP045145A/es unknown
- 2004-06-09 CO CO04054292A patent/CO5590907A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042904A patent/NO20042904L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1620082T1 (sl) | Medicinska uporaba inhibitorjev glutaminil in glutamat ciklaz za zdravljenje Alzheimerjeve bolezniin Downovega sindroma | |
| NZ334168A (en) | Combination therapy for treatment of psychoses comprising administering an atypical antipsychotic such as olanzapine, in combination with an effective amount of a serotonin reuptake inhibitor | |
| JP2007516193A5 (cg-RX-API-DMAC10.html) | ||
| EP1656096A4 (en) | METHOD FOR REDUCING THE INFECTION RISK OF ATTACKERS | |
| NO20041833L (no) | Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet | |
| MA28871B1 (fr) | Derives tricycliques accoles pour le traitement de troubles psychotiques | |
| EP1641748A4 (en) | N-ALKYLPHENYLCARBOXAMIDE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| EP2063889A4 (en) | SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| MA28791B1 (fr) | Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux | |
| MA28555B1 (fr) | Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central | |
| MXPA05013733A (es) | 2-aminobenzotiazoles como agonistas inversos del receptor de cb1. | |
| MXPA05013869A (es) | Metabolito de quetiapina. | |
| WO2001076599A8 (en) | Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE60014339T8 (de) | Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren | |
| EE200100136A (et) | Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon | |
| WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| DE60113310D1 (de) | Verfahren zum Abschreckgiessen zur Herstellung von Gussteilen mit eingegossenen Kanälen | |
| MA29085B1 (fr) | Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil | |
| JP2005522432A5 (cg-RX-API-DMAC10.html) | ||
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| WO2004082584A3 (en) | 5ht2c receptor antagonists in the treatment of schizophrenia | |
| PL1828151T3 (pl) | Pochodne malonoamidów jako inhibitory gama-sekretazy do leczenia choroby alzheimera | |
| PL1631296T3 (pl) | Pochodne amidu kwasu 2,3,4,5,-tetrahydrobenzo[f][1,4]oksazepino-5-karboksylowego jako inhibitory gamma-sekretazy do leczenia choroby Alzheimera | |
| CO5590907A2 (es) | Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento de fallo cognitivo |